Abstracts increased 161.8%, and any oxycodone-containing compound increased 267.3%. Mentions of each of these three classes of opioids remained less than 2% of all total drug mentions per year for each year studied. Medical use of the selected opioid classes, as reported in the ARCOS database and measured by grams distributed, all increased substantially (fentanyl 151.2%, morphine 48.8%, oxycodone 347.9%). CONCLUSIONS: Using this method of analysis, the rates of drug abuse, and resultant morbidity secondary to the use of opioid analgesics, remains low in spite of the increase in medical use of these substances. From 1996From to 1999, the use of opioid was not significantly different across different gender or racial/ethnical groups, but significantly higher among individuals who were publicly insured, had low or below low income and had education at or below 12th grade compared to their respective counterparts. During the 4-year period, significant variations in opioid use across different age groups or geographic regions were observed in early years. But the variations became nonsignificant in later years. RESULTS: Trend analysis indicated that the rates of overall opioid use increased slightly across the 4-year span. Among individual opioid categories, the use of oxycodone or hydrocodone increased whereas the use of propoxyphene decreased. CONCLUSIONS: The significantly higher use of opioids among individuals who were publicly insured, had low or below low income and had education at or below 12th grade raised serious concerns about drug safety in this patient population. The increase in the use of hydrocodone and oxycodone indicated a need to better assess the efficacy and safety associated with these drugs among individuals with back pain. There is a lack of information on national prescription patterns of NSAIDs and muscle relaxants among individuals with back pain in the US. METHODS: Traditional NSAIDs, cyclooxygenase-2-specific (COX-2) inhibitors and muscle relaxants were investigated. Individuals with back pain were stratified by socio-demographic characteristics and geographical regions. For each medication category, overall prescribing frequency was compared across different strata and individual drug prescription was analyzed. RESULTS: Traditional NSAIDs, COX-2 inhibitors and muscle relaxants respectively accounted for 16.3%, 10% and 18.5% of total prescriptions for back pain in 2000. Among individual drugs, ibuprofen and naproxen accounted for most of the prescriptions for traditional NSAIDs (60%), whereas two-thirds of the prescriptions for muscle relaxants were attributable to cyclobenzaprine, carisoprodol and methocarbamol. Prescription of COX-2 inhibitors or muscle relaxants demonstrated wide variations across different regions. Several individual characteristics including age, race and educational level were associated with the prescription of some of the medications. CONCLU-SIONS: Neither traditional NSAIDs, nor COX-2 inhibitors, nor muscle relaxants dominated prescriptions for back pain. However, a small number of individual drugs were attributable to most of the prescriptions for traditional NSAIDs or muscle relaxants. The prescription of some of the medications demonstrated wide variations across different regions or different racial and educational groups. More studies are needed to understand why the variations occurred and how to standardize the prescriptions.
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METHODS
METHODS-Cost Related Studies
PMD1 COMPARISON OF GENERALIZED LINEAR MODELS AND ORDINARY LEAST-SQUARES REGRESSION FOR COST ESTIMATION
Ollendorf DA, Pedan A PharMetrics Inc, Watertown, MA, USA OBJECTIVES: To illustrate how use of generalized linear models to analyze health care cost data may provide a better distributional fit than commonly employed approaches (e.g., linear or log-linear ordinary least squares [OLS] regression), and could yield quantitatively and inferentially different conclusions. METHODS: Data were obtained from the PharMetrics PatientCentric Database, which includes integrated medical pharmacy claims from 73 health plans nationwide. Patients with a diagnosis of intermittent claudication (ICD-9-CM 443.9x) who newly started cilostazol or pentoxifylline therapy between June 1999-March 2002 were selected for analysis. Six-month pretreatment and follow-up periods were created in relation to the first observed prescription. Total costs of care during follow-up were estimated based on health plan payments for medications and services rendered, and were expressed in 2002 U.S. dollars. Alternative multivariate approaches to analyzing total costs were employed-an OLS model (log-linear) versus a generalized linear model (GLM) with a log-link function and a gamma distribution. Covariates included demographic and other baseline/ pretreatment variables. Histograms of untransformed and logtransformed costs were compared to gamma and normal distributions; goodness-of-fit assessments also were conducted. The results of OLS (on a log-transformed outcome) and gamma GLM models were compared. RESULTS: Analyses were conducted for 763 and 506 patients newly starting cilostazol and pentoxifylline therapy respectively. The results of goodness-of-fit testing (deviance: 1489.5 vs. 1366.4 for degrees of freedom = 1,255) indicated that the gamma GLM model approximated the cost distribution most closely. Observed annual mean total costs were $6238 and $5568 for cilostazol and pentoxifylline respectively; application of the two models yielded different results-a nonsignficant (p = 0.0620) treatment effect using log-linear OLS, and
